TY  - JOUR

T1  - LBA102 THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment

JO  - Annals of Oncology

UR  - http://dx.doi.org/10.1016/j.annonc.2023.10.108

PY  - 2023/10/01

AU  - Catto JWF

AU  - Tran B

AU  - Roupret M

AU  - Gschwend JE

AU  - Loriot Y

AU  - Nishiyama H

AU  - Palou J

AU  - Daneshmand S

AU  - Hussain SA

AU  - Cutuli HJ

AU  - Procopio G et al

ED  - 

DO  - DOI: 10.1016/j.annonc.2023.10.108

PB  - Elsevier BV

VL  - 34

SP  - S1341

EP  - S1342

Y2  - 2024/12/28

ER  -